CNS Correlates of Extended Sleep Restriction
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Vincent F Capaldi, MD
- Phone Number: 301-319-9098
- Email: vincent.f.capaldi.mil@health.mil
Study Contact Backup
- Name: Samantha M Riedy, PhD
- Phone Number: 301-319-3944
- Email: samantha.m.riedy.civ@health.mil
Study Locations
-
-
Maryland
-
Silver Spring, Maryland, United States, 20910
- Walter Reed Army Institute of Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
- Ages 18 to 39 (inclusive)
- A body mass index (BMI) below 30.
- Weigh at least 140 lbs
- Females must not be pregnant or nursing, and must be on some form of birth control, if sexually active (e.g., oral contraceptive, condom, intrauterine device, etc.)
- No history of sleeping problems such as insomnia or sleep apnea.
- Test negative for alcohol, nicotine, illegal drugs, and not take certain medications.
- Must not excessively consume alcohol or caffeine.
- Active duty and Federal employees must be on leave during participation.
- No history of heart disease (high blood pressure), neurologic disorder (such as seizures of epilepsy), liver disease, kidney disease, or metabolic disorder or diabetes.
- No history of underlying acute or chronic pulmonary disease requiring daily inhaler use.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Positron Emission Tomography (PET) based measurement of neuroinflammation
Time Frame: 3 Days
|
Positron Emission Tomography (PET) is the brain imaging method and [11C]ER176 is the PET radioligand providing an index of neuroinflammation
|
3 Days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Psychomotor Vigilance Task (PVT)
Time Frame: 55 Days
|
Measure of cognitive performance
|
55 Days
|
|
Actigraphy
Time Frame: 55 Days
|
Activity monitoring used to infer sleep-wake patterns
|
55 Days
|
|
Polysomnographic measurements of sleep and wakefulness
Time Frame: 19 Days
|
Measure of various aspects of sleep and wakefulness
|
19 Days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2804
- MO220146 (Other Grant/Funding Number: Military Operational Medicine Research Program)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.